PBR Nachrichten

 

The approval covers both adult and paediatric patients aged eight years and above. GSDIa is a rare genetic metabolic disorder caused by a deficiency in the enzyme required The post FDA grants accelerated approval to Ultragenyx's Genglycos gene therapy appeared first on Pharmaceutical Business review....

AQPotency is accessible through Claude via the Model Context Protocol (MCP), as well as through the SandboxAQ website, with plans for listing on Google Cloud's Marketplace. It enables The post SandboxAQ introduces AQPotency for virtual drug screening appeared first on Pharmaceutical Business review....

The partnership aims to progress this gene therapy using Andelyn's AAV Curator Platform. GM2 gangliosidosis is a rare genetic disorder that leads to the progressive loss of nerve The post Andelyn Biosciences to develop GM2 gangliosidosis therapy appeared first on Pharmaceutical Business review....

The renewed agreement is expected to reach approximately 1,000 patients cumulatively by its conclusion. This partnership, which began in 2023, has so far provided Brukinsa to more than The post BeOne Medicines and partners renew Brukinsa access programme for CLL appeared first on Pharmaceutical Business review....

The designation applies specifically to patients whose tumours contain a phosphatidylinositol 3-kinase / protein kinase B / mechanistic target of rapamycin (PI3K/AKT/mTOR) pathway alteration. It also applies to The post Faeth's PIKTOR plus paclitaxel combo gains FDA fast track status appeared first on Pharmaceutical Business review....

The combined organisation, which will operate as Slate Medicines, is expected to be listed on Nasdaq under the “SLTE” ticker symbol. Following completion of the merger, the new The post Fulcrum and Slate Medicines sign merger agreement appeared first on Pharmaceutical Business review....

With this validation, the agency will begin its formal assessment of the application. The submission is supported by efficacy and safety data from the Phase III VALOR clinical The post EMA validates Pfizer and Valneva's Lyme disease vaccine appeared first on Pharmaceutical Business review....

The company is evaluating spevatamig in Phase II clinical studies for various gastrointestinal cancers. Spevatamig is a bispecific antibody targeting claudin 18.2 and cluster of differentiation 47 (CD47), The post FDA grants fast track status to Phanes' spevatamig for advanced BTC appeared first on Pharmaceutical Business review....

The collaboration aims to develop new quantum algorithms that could accelerate the design of next-generation photosensitisers for photodynamic therapy, a non-invasive treatment approach targeting tumour cells. The project The post Xanadu and University of Alberta to develop quantum algorithms for cancer appeared first on Pharmaceutical Business review....

The combination is intended for patients who have previously received at least one line of therapy that included both a proteasome inhibitor and an immunomodulatory agent. Zenbexus is The post BMS secures FDA accelerated approval for Zenbexus in multiple myeloma appeared first on Pharmaceutical Business review....

The decision marks the third NMPA-approved indication for an ivonescimab-containing regimen in the country since the molecule first received authorisation in May 2024. Ivonescimab is described as an The post Akeso secures China NMPA authorisation for ivonescimab combo appeared first on Pharmaceutical Business review....

The proceeds will also be used to fund Remepy's lead product Hybridopa's global Phase III clinical trial targeting Parkinson's disease (PD). It is set to commence in the The post Remepy secures $36m funding for hybrid drug pipeline expansion appeared first on Pharmaceutical Business review....

The arrangement enables Sentynl to acquire exclusive US commercial rights to alvelestat upon exercise of the option while Mereo BioPharma will retain commercial rights outside the US. Under The post Mereo BioPharma and Sentynl Therapeutics sign licensing deal for alvelestat appeared first on Pharmaceutical Business review....

The transaction is structured through a share purchase agreement with SEVER Life Sciences for 100% of Nordic Group and its subsidiaries. While specific financial terms have not been The post Alfasigma signs agreement to acquire Nordic Group appeared first on Pharmaceutical Business review....

The deal includes joint studies combining BeOne's cancer pipeline assets with four clinical-stage RAS(ON) inhibitors from Revolution Medicines, alongside a regional rights agreement for select Asian markets. The The post BeOne and Revolution Medicines partner for oncology therapies appeared first on Pharmaceutical Business review....

Unanimously approved by both companies' boards, the transaction is expected to close by the fourth quarter (Q4) of 2026, pending customary closing conditions. Jazz Pharmaceuticals plans to fund The post Jazz Pharmaceuticals to acquire Actio Biosciences for $820m upfront appeared first on Pharmaceutical Business review....

Under the contract, Daiichi Sankyo will continue to handle development, manufacturing, and supply of the therapy while Innovent Biologics will lead market promotion and commercialisation activities in China. The post Innovent and Daiichi Sankyo sign deal for Vanflyta in China appeared first on Pharmaceutical Business review....

The collaboration will focus on process technology transfer and activities relating to chemistry, manufacturing and controls (CMC) to support a possible new drug application (NDA) in Taiwan for The post Energenesis and Taiwan Tanabe to develop ENERGI-F703DFU for DFUs appeared first on Pharmaceutical Business review....

These conditions often result in organ failure due to myofibroblast activation, scarring, and tissue inflammation. Ono will work alongside Mediar to utilise its fibrosis-focused discovery platform, expertise in The post Mediar and Ono Pharmaceutical to develop fibro-inflammatory treatments appeared first on Pharmaceutical Business review....

This collaboration will focus on utilising Evotec's data-driven discovery platform alongside its AI data science and advanced screening technologies. It aims to accelerate the discovery and validation of The post Evotec and Odyssey collaborate on AI-enabled R&D appeared first on Pharmaceutical Business review....